Terumo: Antoinette Gawin becomes Group Managing Executive Officer
Antoinette Gawin, CEO of Terumo Blood and Cell Technologies, has been appointed to parent company Terumo Corporation’s board as Group Managing Executive Officer.
The move comes as Terumo redefines its internal management system to support its expanding global operations, enhance competitiveness on a global scale, and achieve its five-year plan.
Terumo has shifted its business from predominantly “in Japan for Japan” to becoming a global healthcare company. Today, about 67% of Terumo’s revenue is generated outside of Japan, driven in part by the growth of Terumo Blood and Cell Technologies under Gawin’s leadership and the steady expansion of Terumo’s Cardiac and Vascular businesses.
The newly formed GMEO position will directly shape strategy across all Terumo operating entities. Gawin is the only female and only non-Japanese leader ever to serve in this capacity. She will continue participating in Terumo’s Executive Management Meeting (EMM) as a core member.
Gawin’s vision for Terumo Blood and Cell Technologies led to its successful return to growth, achieving $1bn sales in each of the last three years since she took the helm as CEO. She led the strategic shift to blood and beyond, including entrance to the source plasma industry and double-digit growth in the cell and gene therapy sector.
The company has also collaborated with Immunicom to launch breakthrough cancer immunotherapy treatment in Europe.
“Gawin is helping to shape customer environments with an ecosystem of automation, services and enterprise software that improves patient access to safe and adequate blood and cells. The company’s upgraded infrastructure and delivery system are foundational and were successfully tested during COVID-19 as production rapidly flexed to meet demand shifts and support the global collection of convalescent plasma,” says the company.
